je.st
news
Tag: announces results
KMG EP announces results of exploratory appraisal well at Rozhkovskoye field, Kazakhstan
2016-11-08 01:00:00| Hydrocarbons Technology
JSC KazMunaiGas Exploration Production (KMG EP) has announced the results of an exploratory appraisal well at the Rozhkovskoye field, located within the Fedorovsky block in Kazakhstan.
Tags: results
field
kazakhstan
announces
Condor Petroleum announces drilling results of development well in Turkey
2016-11-02 01:00:00| Hydrocarbons Technology
Condor Petroleum has reported drilling results of the Poyraz 3 development well in Turkey.
Tags: results
development
turkey
announces
Asian Paints Announces Q2-FY17 Results
2016-10-25 16:12:00| Coatings World Breaking News
Tags: results
asian
announces
paints
Merck Announces Third-Quarter 2016 Financial Results
2016-10-25 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Third-Quarter 2016 Worldwide Sales Were $10.5 Billion, an Increase of 5 Percent, Including a 1 Percent Negative Impact from Foreign Exchange Third-Quarter 2016 GAAP EPS Was $0.78; Third-Quarter Non-GAAP EPS Was $1.07 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS to be Between $2.02 and $2.09; Full-Year 2016 Non-GAAP EPS to be Between $3.71 and $3.78 Advanced KEYTRUDA Development Program FDA Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) New Data Were Included in Labeling for KEYTRUDA Showing Improved Survival Compared to Chemotherapy in Previously Treated Patients with NSCLC Whose Tumors Express PD-L1 (TPS of 1 Percent or More) FDA Approved KEYTRUDA to Treat Previously Treated Recurrent or Metastatic Head and Neck Cancer KEYNOTE-045 Study Evaluating KEYTRUDA in Previously Treated Advanced Bladder Cancer (Urothelial Cancer) Met Primary Endpoint of Overall Survival and Stopped Early KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces Second-Quarter 2016 Financial Results
2016-07-29 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77 Advanced KEYTRUDA Development Program KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »